Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential ipilimumab vs best supportive care after first-line chemotherapy in advanced gastric or gastro-esophageal junction cancer
jRCT2080222028Phase 2
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Ipilimumab arm with Best supportive care arm (2 arms).
02
Drugs
ipilimumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080222028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222028.